EnWave Corporation (TSX VENTURE: ENW.V) ("EnWave" or "the Company") today announced that it has successfully dried three different antibodies in the Company's prototype freezeREV vial dehydration technology. Results from this study showed no detectable visual difference between freezeREV-dried and freeze dried samples when examined with the SDS-PAGE electrophoresis method. Additionally, the indication of the molecular weight was similar between the two dried samples and liquid antibodies. Freeze drying, or lyophilization, is the current industry standard for dehydrating live or active organisms such as antibodies.
Freeze drying can be particularly harsh on sensitive materials such as antibodies because of the length of time the organisms are exposed to extremely low temperatures.
The freezeREV prototype has been designed to significantly reduce the drying time and temperature exposure from days, to minutes or hours, creating the potential for a high-speed, cost effective dehydration technology. The Company believes that a commercial-scale freezeREV machine could reduce the costs of dehydration for live or active pharmaceuticals and reagents by as much as 80%.
"These are exciting results for the Company as we are seeing the potential of this technology in a new area of biopharmaceuticals and biomaterials," said Dr. Durance. "We have tested a variety of proteins in the past, but antibody dehydration could open up a huge new market for EnWave, and this would compliment our existing research into vaccine dehydration."
Antibodies are infection fighting proteins used in a wide variety of applications including medical research and diagnostics, prenatal therapy, and treatment of diseases such as cancer, heart disease, rheumatoid arthritis and multiple sclerosis. The three polyclonal antibodies used in this study were derived from chicken, rabbit and bovine blood serum, and are used by the pharmaceutical industry for drug research. They are also used in the production of animal vaccines, and as feed additives to improve animal health. Dehydration of antibodies is important to the pharmaceutical and biotechnology sectors, primarily because the process increases the shelf-life of these expensive and difficult-to-manufacture organisms.
freezeREV is a method for drying biomaterials in vials where low moisture levels in the final product are imperative for long product shelf-life. This technology is being designed to create room temperature stable pharmaceuticals or reagents containing live organisms such as viruses, bacteria and antibodies where an emphasis must be placed on maintaining the maximum possible survival rates of these organisms until they are delivered to a patient.
EnWave has initiated a search for a major industry partner with whom to expand testing for both polyclonal and monoclonal antibody products with the goal of proving that freezeREV dehydration technology can be developed into a commercially viable method.
About EnWave
Using proprietary technologies developed in conjunction with the University of British Columbia, EnWave is focused on the development of new methods of dehydrating food and biological materials using Radiant Energy Vacuum technology under its nutraREVTM, powderREV, bioREVTM and freezeREV brands. REV technology combines microwave energy transfer under vacuum to dehydrate and alter structures and drive chemical reactions, thereby creating unique product characteristics for both food products and medical applications that include fruit, vegetables, probiotics, enzymes, proteins, food cultures, vaccines and antibodies. More information about EnWave is available at www.enwave.net.
EnWave Corporation
Dr. Tim Durance, Chairman & Co-CEO
This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions: there is no guarantee that the Company's REV technology can or will improve dehydration processes in the target industries; even if the Company's REV technology can be used as described in this document, there is no guarantee that such use will result in orders for the Company's REV technology.
The TSX Venture Exchange has neither approved nor disapproved the information contained herein.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts
Dr. Tim Durance
EnWave Corporation
Chairman & Co-CEO
(604) 822-4425
This email address is being protected from spambots. You need JavaScript enabled to view it.
Jennifer Thompson
EnWave Corporation
V.P. Corporate Development & Investor Relations
(604) 603-6549
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.enwave.net